Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors

US4571385A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Harry Greenberg · Washington, US
• Richard G. Wyatt · Potomac, US
• Albert Z. Kapikian · Rockville, US
• Anthony R. Kalica · Rockville, US
• Karen Midthun · Sharpsburg, US
• Robert M. Chanock · Bethesda, US

Key dates

• Filing date: Jun 27, 1983
• Grant date: Feb 18, 1986
• Expiry date: Jun 27, 2003

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2720/12361
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.